Affordable Access

Access to the full text

Association between partial-volume corrected SUVmax and Oncotype DX recurrence score in early-stage, ER-positive/HER2-negative invasive breast cancer

Authors
  • Lee, Su Hyun1
  • Ha, Seunggyun2, 3
  • An, Hyun Joon2, 4
  • Lee, Jae Sung2, 4
  • Han, Wonshik5
  • Im, Seock-Ah6
  • Ryu, Han Suk7
  • Kim, Won Hwa8
  • Chang, Jung Min1
  • Cho, Nariya1
  • Moon, Woo Kyung1, 9, 10
  • Cheon, Gi Jeong2, 9, 10
  • 1 Seoul National University College of Medicine, Department of Radiology, Seoul National University Hospital, Seoul, South Korea , Seoul (South Korea)
  • 2 Seoul National University College of Medicine, Department of Nuclear Medicine, Seoul National University Hospital, Seoul, South Korea , Seoul (South Korea)
  • 3 Seoul National University, Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, and College of Medicine or College of Pharmacy, Seoul, South Korea , Seoul (South Korea)
  • 4 Seoul National University College of Medicine, Department of Biomedical Sciences, Seoul, South Korea , Seoul (South Korea)
  • 5 Seoul National University College of Medicine, Department of Surgery, Seoul National University Hospital, Seoul, South Korea , Seoul (South Korea)
  • 6 Seoul National University College of Medicine, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea , Seoul (South Korea)
  • 7 Seoul National University College of Medicine, Department of Pathology, Seoul National University Hospital, Seoul, South Korea , Seoul (South Korea)
  • 8 Kyungpook National University Hospital, Department of Radiology, Daegu, South Korea , Daegu (South Korea)
  • 9 Seoul National University College of Medicine, Cancer Research Institute, Seoul, South Korea , Seoul (South Korea)
  • 10 Seoul National University College of Medicine, Radiation Medicine Research Institute, Seoul, South Korea , Seoul (South Korea)
Type
Published Article
Journal
European Journal of Nuclear Medicine
Publisher
Springer-Verlag
Publication Date
May 21, 2016
Volume
43
Issue
9
Pages
1574–1584
Identifiers
DOI: 10.1007/s00259-016-3418-1
Source
Springer Nature
Keywords
License
Yellow

Abstract

PurposeOncotype DX, a 21-gene expression assay, provides a recurrence score (RS) which predicts prognosis and the benefit from adjuvant chemotherapy in patients with early-stage, estrogen receptor-positive (ER-positive), and human epidermal growth factor receptor 2-negative (HER2-negative) invasive breast cancer. However, Oncotype DX tests are expensive and not readily available in all institutions. The purpose of this study was to investigate whether metabolic parameters on 18F-FDG PET/CT are associated with the Oncotype DX RS and whether 18F-FDG PET/CT can be used to predict the Oncotype DX RS.MethodsThe study group comprised 38 women with stage I/II, ER-positive/HER2-negative invasive breast cancer who underwent pretreatment 18F-FDG PET/CT and Oncotype DX testing. On PET/CT, maximum (SUVmax) and average standardized uptake values, metabolic tumor volume, and total lesion glycolysis were measured. Partial volume-corrected SUVmax (PVC-SUVmax) determined using the recovery coefficient method was also evaluated. Oncotype DX RS (0 – 100) was categorized as low (<18), intermediate (18 – 30), or high (≥31). The associations between metabolic parameters and RS were analyzed. Multivariate logistic regression was used to identify significant independent predictors of low versus intermediate-to-high RS.ResultsOf the 38 patients, 22 (58 %) had a low RS, 13 (34 %) had an intermediate RS, and 3 (8 %) had a high RS. In the analysis with 38 index tumors, PVC-SUVmax was higher in tumors in patients with intermediate-to-high RS than in those with low RS (5.68 vs. 4.06; P = 0.067, marginally significant). High PVC-SUVmax (≥4.96) was significantly associated with intermediate-to-high RS (odds ratio, OR, 10.556; P = 0.004) in univariate analysis. In multivariate analysis with clinicopathologic factors, PVC-SUVmax ≥4.96 (OR 8.459; P = 0.013) was a significant independent predictor of intermediate-to-high RS.ConclusionsHigh PVC-SUVmax on 18F-FDG PET/CT was significantly associated with an intermediate-to-high Oncotype DX RS. PVC metabolic parameters on 18F-FDG PET/CT can be used to predict the Oncotype DX RS in patients with early-stage, ER-positive/HER2-negative breast cancer.

Report this publication

Statistics

Seen <100 times